Philips said Wednesday that it has agreed with Lunit and Vuno to conduct R&D for technology-based healthcare AI in Korea and commercialize the developed solutions to local and overseas medical institutions after clinical trials.
|From left, Vuno CEO Lee Ye-ha, Philips Korea CEO Kim Dong-hee and Lunit CEO Suh Beom-seok hold up their agreements at Philips headquarters in downtown Seoul, on Wednesday.|
Lunit and Vuno are leading medical artificial intelligence (AI) solution companies.
“Recently, the medical and healthcare industries have been using AI technology to effectively utilize vast amounts of medical data to make a preventive and precise diagnosis and precision medical care,” the company said. “However, for the AI technology to work in the clinical field, it is necessary to have standardized abundant learning case data and verified clinical validity and accuracy for the AI.”
To help with the process, Philips offers “Philips IntelliSpace Discovery,” healthcare AI open research platform.
“Aside from assisting medical staffs, the platform also helps AI solution providers such as Lunit and Vuno through their entire AI development process from preparing learning data to clinical verification and real clinical environment introduction in hospitals,” the company said.
Also, the platform's MarketPlace feature enables networks to share AI algorithms with overseas medical institutions in North America and Europe, which in turn, helps companies to conduct collaborative research and clinical validation worldwide, it added.
Under the accord, the three companies will develop a healthcare AI solutions centered on Korean technology and work closely together to ensure that they can commercialize the solution not only in Korea but abroad.
“We will actively share our advanced technology and know-how to medical staff and local healthcare AI development companies to develop solutions that will lead the global healthcare AI field,” Philips Korea CEO Kim Dong-hee said. “The company hopes that this cooperation agreement will help Korea to strengthen its global competitiveness in the healthcare AI field.”
<© Korea Biomedical Review, All rights reserved.>